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doi:10.1016/j.ejvs.2009.11.025Abstract Objectives: To assess whether routine use of foam sclerotherapy, in addition to
four-layer compression bandaging, could speed up the healing of venous ulcers.
Design: Randomised controlled trial involving patients recruited from a nurse-led leg ulcer
clinic. A total of 315 new patients were assessed, and eleven patients were identified from
follow-up clinics.
Methods: Inclusion criteria were: patients with an active venous leg ulcer, in the presence of
superficial truncal venous incompetence and without total deep venous incompetence on
duplex imaging. Patients were randomised to four-layer compression bandages alone (control)
or with additional foam sclerotherapy to incompetent superficial truncal veins. The primary
endpoint was ulcer healing 24 weeks after randomisation.
Results: It was only possible to recruit 40 patients who were suitable for analysis: 22 control,
18 additional foam sclerotherapy. There was no complication from the foam treatment and at
six months the target vein was occluded in 9 of 11 evaluable patients that had foam. One
patient died before 24 weeks from an unrelated cause. At 24 weeks, 17 of 20 (85% - 1 died)
in the control group and 12 of 13 (92%) patients with additional foam sclerotherapy had ulcer
healing (PZ0.72, log rank testing).
Conclusion: This trial failed to recruit sufficient patients for formal comparison, but foam
sclerotherapy was feasible as an adjunct to compression therapy for venous ulceration. Trial
registration: Eudra CT 2005-001551-38
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Venous leg ulcers affect 1% of the adult population and are
particularly prevalent in those over 80 years of age.1e3454226190; fax: þ44 845422
tiscali.co.uk, jonothan.
).
ty for Vascular Surgery. PublisheFour-layer compression bandaging has become the standard
treatment for these patients and has been shown to opti-
mise ulcer healing rates at 3 months.4 After ulcer healing
the wearing of compression stockings then reduces the rate
of ulcer recurrence.5 There is strong evidence that surgical
correction of superficial venous incompetence in addition
to four-layer compression bandaging, in patients with
venous leg ulceration, significantly reduces ulcer recur-
rence at 12 months6 and has continued benefit at 4 years.7d by Elsevier Ltd. All rights reserved.
496 J.L. O’Hare, J.J. EarnshawAdditional surgery, however, has no effect on the speed of
ulcer healing. van Gent found that subfascial endoscopic
perforating vein surgery, combined with traditional surgery
where indicated, led to a longer ulcer-free period in
patients with recurrent or medial ulcers than compression
therapy alone.8
Many patients with a venous leg ulcer are elderly and do
not want, or are not fit for venous surgery under general
anaesthesia. A number of authors have described their
experience of using foam sclerotherapy in patients with
a venous leg ulcer. Foam sclerotherapy works by occluding
the superficial incompetent vein, thereby removing its
contribution to the chronic venous hypertension, thought to
play a major role in venous ulceration.9 In addition, there
are logistical advantages for foam treatment, compared
with surgery, that mean it may be possible to influence the
healing rate of a venous ulcer as well as the potential for
recurrence. Cabrera has described a series of 116 patients
with a 6 month ulcer healing rate of 83%.10 Bergan reported
a series of 12 patients with ulcers that failed to heal after
compression therapy.11 Nine of these healed within 2 weeks
and all healed within 6 weeks of foam sclerotherapy.
The aim of the present study was to assess whether
routine use of additional foam sclerotherapy in patients
with venous leg ulceration treated with four-layer
compression bandaging could speed up ulcer healing.Materials and methods
Consecutive new patients attending a one stop nurse-led leg
ulcer clinicwith an active venous leg ulcer (CEAP clinical class
C6), and superficial truncal venous incompetence were
assessedprospectively. Criteria for inclusion in the studywere
>1 s retrograde flow on venous duplex imaging in the great
saphenous vein (GSV), small saphenous vein (SSV), anterior
accessory saphenous vein (AASV) or other large superficial
vein with significant proximal deep venous connection, and
without total deep venous incompetence. Patients with an
ankle brachial pressure index (ABPI)<0.8, previous deep vein
thrombosis (DVT) or pulmonary embolism (PE), poorly
controlled diabetes, rheumatoid arthritis, malignancy,
immobility, those currently taking warfarin and those unable
to give informed consent were excluded. In addition, patients
with chronic venous ulcers attending the leg ulcer follow-up
clinic were considered for the study if they met the inclusion
criteria. The study was approved by the Trust Ethics
Committee and all participants provided written consent.
Participating patients were randomised to four-layer
compression bandages alone (control) or with additional
foam sclerotherapy using sealed opaque envelopes con-
taining computer generated random numbers. For those
randomised to the foam sclerotherapy group this was
carried out as soon as practicable to allow time to assimi-
late trial information and to fit in with routine follow-up in
the leg ulcer clinics (usually within 2e4 weeks of the initial
clinic visit) using the method described previously.12
Briefly, the GSV was usually cannulated with a 20G or 18G
cannula just above the knee under ultrasound guidance.
The distal GSV or other prominent tributaries were often
entered separately with a butterfly needle. Venepuncture
was avoided through damaged or vulnerable skin near thearea of ulceration. The cannula or butterfly was then
flushed with normal saline both to clear it of blood and to
confirm its position within the vein by visualising flow in the
proximal vein on duplex ultrasound imaging. The patient’s
leg was then elevated to 45 in a sling or, for posterior
veins, by tilting the bed. Foam was produced by a modified
Tessari method: 0.5 ml 3% sodium tetradecyl sulphate was
mixed with 1.5 ml of room air between two 2 ml syringes via
a three-way tap. Foam was injected in 2 ml boluses and
progression of foam along the target vein was observed
during injection by ultrasound imaging. Between each
injection the patient was encouraged to plantar- and dorsi-
flex the ankle to speed blood flow in the deep veins to flush
away any foam that escaped. Foam was injected until it
was evident just proximal to the incompetent junction with
the deep vein on ultrasound. Other tributaries were also
filled with foam until occluded; a maximum total volume of
14 ml was used per treatment session. The aim was to
obliterate major truncal reflux; incidental incompetent
perforating veins were not specifically treated. After
treatment, eccentric compression was achieved using
a four-layer strip of cotton wool roll placed directly over
the treated vein secured with a Peha-Haft bandage and
secured with a thromboembolic deterrent (TED) stocking
for 5 days. Patients then went back into four-layer
compression bandages until the ulcer healed.
All patients were seen every 3 weeks in the leg ulcer
clinic until their ulcer healed. They were then reviewed 12
and 24 weeks after randomisation. Venous duplex imaging
was undertaken 6 weeks after foam sclerotherapy and at
24 weeks after randomisation to assess target vein patency
and examine the deep veins. The primary endpoint of the
study was ulcer healing 24 weeks after randomisation.
Using data for median ulcer healing time (92 and
56 days) and percentage healed at 24 weeks (67% and 86%)
from studies by Nelson13 and Cabrera,10 it was calculated
that 170 patients would need to be randomised and
followed to 6 months to detect a significant improvement in
ulcer healing with foam with 80% power.Results
Of 315 new presentations to the leg ulcer clinic from
October 2005 to September 2007, 72 patients met the trial
entry criteria. Of the remainder, 107 had no superficial
venous incompetence, 45 had no active ulcer, 40 had total
deep venous incompetence and 46 had an ABPI of <0.8.
Fifty-one patients had a history of DVT and/or PE, 23 were
currently taking warfarin, 5 had rheumatoid arthritis and 3
had a malignancy. Of otherwise suitable patients 3 were
unable to tolerate compression bandaging, 3 were immo-
bile and 6 were unable to give informed consent. A further
11 patients with chronic non-healing venous ulcers were
enrolled from follow-up leg ulcer clinics.
A total of 40 patients consented to be included; 18 were
randomised to additional foam sclerotherapy and there
were 22 controls. Four patients withdrew from the study
including one who decided to have surgical stripping, one
who chose foam sclerotherapy and one who declined foam
sclerotherapy. Two further patients initially randomised
into the study, were subsequently found on review to have
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34 patients for analysis, 13 of whom had additional foam
sclerotherapy (Fig. 1).
The median age of the trial patients was 69 years (range
33e90 years) and the median duration of their ulcer at
presentation was 14 weeks. Initial median ulcer diameter
was 2.0 cm (range 0.5e10.5 cm). Nine of the 34 ulcers were
recurrent on the same leg. The incompetent superficial
veins were GSV 28, SSV 5, AASV 4, others 5 (8 patients had
two incompetent superficial veins). Four patients had
segmental deep venous incompetence.
Foam sclerotherapy
Of 13 patients randomised to additional early foam scle-
rotherapy, all but one had a single treatment session. One
patient had failure of vein cannulation on the first visit,New leg ulc
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follow-up. Ulcers were healed at 12 weeks in 13 of 21 (62%)
in the control group (one had healed and then recurred)
and 12 of 13 (92%) who had additional foam sclerotherapy.
At 24 weeks after randomisation the respective figures
were: 17 of 20 (85%, 1 died) in the control group and 12 of
13 (92%) who had foam. KapleineMeier analysis of ulcer
healing on the basis of intention to treat is shown in Fig. 2.
Log rank testing showed no significant difference between
the groups (pZ 0.72). The 95% confidence interval for the
ratio of median healing times was 0.17e1.12. Target vein
occlusion rates on duplex imaging were 8 of 10 (80%) at
6 weeks after foam sclerotherapy (3 patients did not
attend) and 9 of 11 (82% 1 died, 1 did not attend) 24 weeks
after randomisation. No patient had a DVT on duplex
imaging at 6 or 24 weeks, but one patient was found to have
new popliteal vein incompetence in their treated leg after
24 weeks.
Discussion
This study was not able to recruit sufficient patients to
enable a secure evaluation of the effect of additional foam
sclerotherapy on the healing of venous ulcers. It does,
however, prove the principle that foam can be added to the
pathway of care for patients with leg ulcers. In addition to
compression bandaging, early foam sclerotherapy appears
to be a safe and effective means of securing superficial vein
occlusion in this group of patients.
Fewer patients than anticipated met the trial entry
criteria, and early healing of ulcers before patients agreed to
randomisation was also a problem. The patients coming to
the leg ulcer clinic seem to be different from those seen
previously. More appear to have chronic and non-venous
ulcers than seen previously in leg ulcer clinics in Glouces-
tershire.12 This may be the result of education concerning
compression treatment reaching the community nurses. The
patients who did agree to be randomised tended to be moreNumber at risk
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Figure 2 KapleineMeier analysis of ulcer healing in a rando-
mised trial of early foam sclerotherapy in patients with
a venous ulcer, on the basis of intention to treat.motivated and complied fully with four-layer compression
bandaging and regular limb elevation. This group of patients
achieved better than average early ulcer healing and lower
than average recurrence rates. Evidence for this can be seen
when comparing 24 week healing rates in the control (85%)
and foam sclerotherapy (92%) groups of this study with the
control (63%) and surgery (63%) groups of the ESCHAR Study
(done through the same leg ulcer clinic).6 Patients in the
study also tended to have relatively small ulcers. Only one
patient in the present study (control group) developed
a recurrent ulcer within the 24 week follow-up.
As suggested by Bergan, good results were observed with
foam sclerotherapy in patients with non-healing venous
ulcers, including those who had difficulty tolerating four-
layer compression therapy or have been poorly compliant
with leg elevation. The ESCHAR Study showed that superfi-
cial venous surgery is an evidence based intervention in
patients with a venous ulcer that reduced the recurrence
rate by almost 50% over 3 years. However, in that study 47 of
242 (19%) patients randomised to surgery eventually
declined that intervention. Patients with a leg ulcer are
often elderly with multiple comorbidities, so they were seen
as ideal candidates for foam occlusion for their superficial
veins instead of surgery at the start of the foam programme
in Gloucester.13 Complete or partial target vein occlusion
was seen in 87% of patients after 6 months in this group.
An alternative to routine use in patients with leg ulcers
would be to employ foam for selected patients. Gohel et al.
tried to define a high risk group likely to get delayed
healing, who might benefit from early surgery (or foam).
They identified increasing age and ulcer chronicity as
independent risk factors for delayed ulcer healing.14 They
also found that prolonged time to ulcer healing and the
presence of superficial venous reflux not treated with
surgery were independent risk factors for ulcer recurrence.
Foam sclerotherapy may currently be indicated in elderly
patients with non-healing or recurrent ulcers as an
alternative to surgery.
Foam sclerotherapy is becoming more accepted as an
alternative to surgery for varicose veins.15,16 A number of
series have now described its efficacy and low complication
rates. It is acceptable to patients and measurably improves
quality of life. It is clearly the cheapest option for the
management of varicose veins when compared to standard
surgery, or newer endovenous thermal ablation techniques.
Its cost efficacy will depend on recurrence rates, and will
not be known until formal comparative trials have been
undertaken. There remains concern about the possibility of
neurological events as a result of treatment, but a recent
report by the National Institute for Health and Clinical
Excellence reviewed the available data and it was decided
that foam could continue to be offered to patients with
varicose veins.17 There are also training issues, since foam
sclerotherapy requires new skills not traditionally taught to
vascular specialists: ultrasound imaging and ultrasound-
guided cannulation.18
So far, only compression bandaging has been shown to
speed up the healing of venous ulcers in clinical trials. The
present research has shown that early foam sclerotherapy
is a feasible component of a comprehensive leg ulcer
service, but larger studies are required before it can be
regarded as the standard of care.
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